GlassScriptPhysician profile
Kimberly K Flory
NPI 1790234987
$4,978.30
in general payments reported to CMS, 2019-2025
26 companies · $110 in 2025
The $110 reported for 2025 was less than what a typical Acute Care (Nurse Practitioner) provider received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $966 · 2022: $1,672 · 2023: $1,810 · 2024: $420 · 2025: $110.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,199 · Education: $141.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,198.77 |
| Education | $140.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $801.61 | 2021-2024 | Cardiomems, Gallant |
| Cvrx, INC. | $501.25 | 2021-2023 | Barostim Neo System |
| Novartis Pharmaceuticals Corporation | $486.02 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $452.59 | 2021-2024 | Verquvo |
| Medtronic, INC. | $382.61 | 2021-2023 | Micra, Azure Xt Dr Mri Surescan |
| Astrazeneca Pharmaceuticals LP | $379.33 | 2021-2023 | Farxiga |
| Janssen Pharmaceuticals, INC | $292.54 | 2021-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $286.23 | 2021-2023 | Jardiance |
| Amgen INC. | $257.68 | 2022-2024 | Repatha |
| E.R. Squibb & Sons, L.L.C. | $190.27 | 2022-2023 | Camzyos, Eliquis |
| Scpharmaceuticals INC. | $146.66 | 2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $121.46 | 2023-2024 | Lifevest |
| Pfizer INC. | $105.06 | 2021-2023 | |
| Kiniksa Pharmaceuticals, LTD. | $97.39 | 2022-2023 | Arcalyst |
| Biowound Solutions, INC. | $78.09 | 2025 | Bio-Connekt |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $67.22 | 2021-2022 | |
| Alnylam Pharmaceuticals INC. | $62.26 | 2022 | |
| Sanofi-Aventis U.S. LLC | $53.03 | 2022-2024 | |
| Novo Nordisk INC | $50.72 | 2024 | Ozempic, Wegovy |
| Kiniksa Pharmaceuticals International, Plc | $34.49 | 2024 | Arcalyst |
| Averitas Pharma INC. | $31.64 | 2025 | Qutenza |
| Bardy Diagnostics, INC. | $26.81 | 2021 | |
| Stryker Corporation | $25.15 | 2023 | N/A |
| Lexicon Pharmaceuticals, INC. | $18.84 | 2023 | Inpefa |
| Actelion Pharmaceuticals US, INC. | $18.20 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $11.15 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Flory listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.